Session
Speaker Patients & Methods:
The study included 16 patients presenting with gastric GISTs and were
candidates for emergency or elective surgery. Patients were enrolled
in 2 groups: A and B (harbouring c-kit +ve tumors). Each B patient
received oral imatinib for 6 months before operation. Assessment was
at day 100 .Chi-square test checked size changes, and p at
< .02535 was considered significant. Conclusion:
Imatinib has an acceptable safety profile and would be considered
as a neoadjuvant therapy in gastric GISTs. 6 months intake may increase
resectability potential and improve prognosis. |